Legend Biotech Corp

Healthcare · Biotechnology

18.80$ +1.1% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Legend Biotech Corp (LEGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,751 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LEGN
Line item	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	288	288	288	288	365	773	709	722	615	875	814	1,119	1,041	1,023	1,331	1,331	1,209	1,931	1,839	1,849	1,775	1,798	1,736	1,670	1,616	1,690	1,713	1,734	1,597	1,751
Current Assets	216	–	–	207	271	673	603	594	475	721	653	950	863	836	1,099	1,099	915	1,613	1,509	1,498	1,414	1,425	1,350	1,284	1,219	1,250	1,242	1,247	1,083	1,227
Cash	-216	–	–	83	169	562	449	456	412	488	338	689	378	380	786	786	660	1,233	963	1,278	898	201	459	287	442	267	279	902	646	673
Cash & Short-Term Investments	216	–	–	159	246	638	576	506	462	693	636	882	791	783	1,026	1,026	850	1,515	1,424	1,309	1,302	1,292	1,212	1,123	1,005	968	993	949	835	965
Receivables	–	–	–	30	23	34	25	83	10	26	15	59	67	43	0.3	45	52	63	50	157	78	101	104	125	167	229	203	250	187	198
Inventory	–	–	–	1.2	1.3	1.7	1.5	1.8	2.1	1.7	1.6	1.7	2.9	8.2	10	10	12	15	18	19	22	19	24	24	31	36	29	32	37	42
Property, Plant & Equipment	–	–	–	–	91	96	104	121	130	143	149	153	163	–	161	161	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	-4.9	-4.9	-4.9	–	–	0.1	0.1	–	–	-94	-94	-119	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	0.5	0.5	1.0	1.0	2.9	4.1	4.7	5.4	17	4.5	4.6	3.4	69	96	122	140	4.1	169	147	175	174	185	201	206	75	35	50
Total Liabilities	–	–	–	411	381	372	374	122	409	535	588	354	602	460	587	587	556	524	500	597	611	639	620	630	598	654	702	732	629	521
Current Liabilities	–	–	–	128	112	115	124	116	146	261	275	229	226	260	298	298	238	201	175	216	250	294	271	278	234	265	434	636	509	404
Short-Term Debt	–	–	–	1.0	1.4	1.3	1.4	1.8	1.5	1.2	1.1	0.9	0.9	2.1	–	3.6	4.6	3.6	2.9	3.2	3.1	3.3	4.3	4.8	5.3	5.9	150	327	277	168
Accounts Payable	–	–	–	9.6	10	7.0	7.4	4.9	9.6	11	12	7.0	9.7	12	33	32	30	22	17	20	39	39	27	37	58	75	102	81	74	77
Long-Term Debt	–	–	–	–	150	–	–	–	–	17	71	120	127	189	–	261	266	271	276	281	286	292	297	301	306	310	172	–	–	–
Shareholders' Equity	8.6	–	–	-123	-16	401	335	598	206	340	226	766	439	563	744	744	653	1,407	1,340	1,251	1,164	1,159	1,116	1,041	1,018	1,036	1,011	1,002	968	1,230
Retained Earnings	–	–	–	-127	-172	–	-117	-117	-603	-603	-729	-520	–	–	-966	-966	-1,278	-1,278	-1,340	-1,485	-1,545	-1,563	-1,688	-1,662	-1,763	-1,888	-1,928	-1,959	-2,013	-1,980
Shares Outstanding	100	100	100	100	129	108	132	132	133	139	145	147	154	155	157	159	165	175	182	182	182	183	183	183	184	184	185	185	185	194

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings